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Abstract: People with coronavirus disease (COVID-19) might have several risk factors for
delirium, which could in turn notably worsen the prognosis. Although pharmacological
approaches for delirium are debated, haloperidol and other first-generation antipsychotics
are frequently employed, particularly for hyperactive presentations. However, the use of these
conventional treatments could be limited in people with COVID-19, due to the underlying
medical condition and the risk of drug–drug interactions with anti-COVID treatments. On these
premises, we carried out a rapid review in order to identify possible alternative medications
for this particular population. By searching PubMed and the Cochrane Library, we selected
the most updated systematic reviews of randomised trials on the pharmacological treatment
of delirium in both intensive and non-intensive care settings, and on the treatment of agitation
related to acute psychosis or dementia. We identified medications performing significantly
better than placebo or haloperidol as the reference treatment in each population considered,
and assessed the strength of association according to validated criteria. In addition, we
collected data on other relevant clinical elements (i.e. common adverse events, drug-drug
interactions with COVID-19 medications, daily doses) and regulatory elements (i.e. therapeutic
indications, contra-indications, available formulations). A total of 10 systematic reviews
were included. Overall, relatively few medications showed benefits over placebo in the four
selected populations. As compared with placebo, significant benefits emerged for quetiapine
and dexmedetomidine in intensive care unit (ICU) settings, and for none of the medications in
non-ICU settings. Considering also data from indirect populations (agitation related to acute
psychosis or dementia), aripiprazole, quetiapine and risperidone showed a potential benefit in
two or three different populations. Despite limitations related to the rapid review methodology
and the use of data from indirect populations, the evidence retrieved can pragmatically
support treatment choices of frontline practitioners involved in the COVID-19 outbreak, and
indicate future research directions for the treatment of delirium in particularly vulnerable
populations.
Keywords: agitation, antipsychotics, coronavirus disease, delirium
Received: 4 May 2020; revised manuscript accepted: 12 June 2020.

Introduction
While we write, the novel coronavirus disease
(COVID-19) pandemic is posing unparalleled
challenges to healthcare systems globally.1 It is estimated that about 1 out of 5 symptomatic cases will
require hospitalisation for medical support, and 1
out of 20 will require intensive-care treatment

because of severe respiratory impairment,2 with
higher fatality rates in older patients with medical
comorbidities.3 As in other life-threatening illnesses
requiring intensive medical support, delirium
occurs frequently and is associated with poorer
prognosis, especially in the elderly.4 A recent report
of 214 cases in China found that about 15% of
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patients with severe COVID-19 developed states
of impaired consciousness, including delirium.5
Delirium is a multifactorial condition, characterised by a wide range of neuropsychiatric abnormalities, typically including changes in attention and
consciousness, sleep problems, delusional thoughts
and hallucinations, anxiety and restlessness, sometimes alongside frank psychomotor agitation. The
disturbance develops quickly (usually hours to
days) and tends to fluctuate over the course of the
day.6 Hypoactive presentations are the most frequent, although agitated/hyperactive presentations
occur in about 25% of patients with delirium.4
People with COVID-19 might have several risk
factors for delirium, including disorientation
caused by hospitalisation, old age, pre-existing
multiple comorbidities and polypharmacy.7,8
Moreover, potentially relevant additional risk factors are prolonged isolation, use of experimental
medical treatments associated with neuropsychiatric side effects (e.g. antimalarial and antiviral
drugs), direct or immunity-mediated neurologic
effects, prolonged mechanical ventilation and
acute renal impairment.9–11

2

respiratory drive and increase the risk of respiratory infections, with worsening of respiratory
distress; (c) the risk of drug–drug interactions
could be relevant, particularly regarding QTcprolongation, due to both altered cytochromes
activity and additive or synergistic activity of medications.16 Therefore, conventional treatment routines are notably limited and should be rapidly
rethought. Recently released guidelines on the
management of delirium in people with COVID19 mostly reflect previous recommendations for
the general population, without fully considering
the peculiarities of these patients and possible challenges of implementing recommendations.17,18
Based on these premises, we conducted a rapid
review of the evidence in order to pragmatically
summarise the elements supporting a tailored
choice of medications for the management of
delirium in people with COVID-19.

Authoritative national and international guidelines recommend non-pharmacological interventions for the prevention and treatment of delirium,
while pharmacological treatments should be
considered only for hyperactive delirium with
important behavioural issues (i.e. agitation,
aggressiveness) or in severely distressed patients.
In these cases, antipsychotics are recommended,
and particularly first-generation antipsychotics,
such as haloperidol or levomepromazine (also
indicated as methotrimeprazine).12,13 However,
the efficacy and safety of antipsychotics for delirium remains actively debated.4 Medications with
anti-histaminergic and anti-cholinergic profiles
can effectively induce short-term sedation, but
medium- and long-term risks might be relevant
(e.g. daytime sedation, respiratory distress and
further worsening of cognitive performance).
Other therapeutic targets of anti-delirium medications might include modulation of neurotransmission, neuroinflammation, oxidative stress and
genetic transcription,14 as well as cognitive
enhancement and recovery.15

Methods
Considering the complete lack of direct data on
delirium in people with COVID-19, we gathered
data in people suffering from four conditions: (a)
delirium in critically ill patients in intensive care
units (ICUs); (b) delirium in non-ICU settings;
(c) dementia-related agitation or aggressiveness;
and (d) psychosis-related agitation or aggressiveness. As psychomotor agitation is a complex manifestation, key triggers and pathophysiology
pathways might significantly differ in different
populations, according to many factors (e.g. age,
underlying medical and psychiatric conditions,
altered states of consciousness). Thus, there are
notable limitations in comparing data from such
different populations. However, from a pragmatic
standpoint, similar medications are generally prescribed to agitated patients irrespective of the
underlying aetiology, probably because they target final common pathways (e.g. dysregulations
of dopaminergic, serotonergic, noradrenergic,
and GABAergic systems).19,20 Furthermore,
although data from indirect populations should
be used carefully to provide practical recommendations,21 they might generate useful insights for
future research on promising interventions.

In patients with COVID-19, the treatment of
hyperactive delirium poses additional challenges,
considering that (a) non-pharmacological prevention and treatment are very limited due to the need
for isolation and few contacts with personnel; (b)
sedative agents might further impair the central

PubMed and the Cochrane Library were searched
for high-quality and updated systematic reviews of
randomised trials (RCTs) on the pharmacological
treatment of delirium or agitation related to
dementia or psychosis. The following terms were
used: (delirium[Title] OR agitat*[Title] OR
journals.sagepub.com/home/tpp
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confus*[Title] OR behav* [Title] OR dementia
[Title]) AND (pharmacother*[Title/Abstract] OR
psychopharm*[Title/Abstract] OR psychotropic*
[Title/Abstract] OR antipsych*[Title/Abstract] OR
benzodiazepin*[Title/Abstract] OR antidepress*
[Title/Abstract]) AND (review[Title]* OR metaanalys*[Title] OR overview[Title] OR synthesis*
[Title] OR random*[Title]). Results were limited
to English language and to the last 10 years. The
search was updated to 20 April 2020. We considered a number of medications typically used
on- and off-label for delirium according to current
clinical guidelines and common practice.
Medications showing statistical superiority over
placebo at study endpoint according to the most
updated meta-analysis of RCTs were defined as
having potential benefit on hyperactive delirium.
When data from placebo-controlled trials were not
available, we considered head-to-head RCTs showing no significant differences against haloperidol
and narrow confidence intervals according to the
GRADE approach for detecting imprecision,21
provided that haloperidol was effective versus placebo in the same population. Strength of associations was assessed with validated criteria commonly
employed to assess the strength of associations
(umbrella review criteria – see Supplemental material).22 Delirium duration or validated rating scales
scores measuring overall symptoms of delirium, or
agitation in the short-term (up to 72 h), were
considered.
In addition, we searched additional sources to
collect data on the pharmacological profile of psychotropic medications and the risk of drug–drug
interactions with COVID-19 medications,16,23,24
as well as regulatory data from the British National
Formulary (BNF) and the European Medicines
Agency (EMA) website.25,26 The following information of practical relevance for the treatment of
delirium in COVID-19 was retrieved for each
medication: sedative and anticholinergic proprieties; risk of QTc prolongation; risk of drug-drug
interactions with COVID-19 medical treatments
(including commonly used antiviral and antimalarial drugs, antibiotics, antirheumatic drugs,
low-molecular-weight heparin); EMA/BNF therapeutic indications; available formulations; and
suggested daily doses according to existing
authoritative guidelines.17,18,23
Results
The database search yielded 342 records. After
removing duplicates, 259 records underwent title
journals.sagepub.com/home/tpp

and abstract screening by one reviewer (CG).
Ultimately, 44 full texts of potentially relevant
studies were independently assessed by two
reviewers (GO, CB), and 10 were finally selected
by agreement (see Supplemental material).27–36
Medications showing evidence of benefit for the
treatment of hyperactive delirium or other forms
of agitation are reported in Table 1, along with
other relevant clinical, pharmacological and regulatory data. Details on the search results, the
study selection, the outcomes extracted from the
selected reviews, the effect sizes and the strength
of association are provided in the Supplement.
Overall, few medications showed potential benefits for the treatment of delirium, and the strength
of associations was always weak according to
the umbrella review criteria. Possible benefits
emerged only for quetiapine and dexmedetomidine in ICU settings. Risperidone, quetiapine,
aripiprazole and sodium valproate were effective
in reducing the level of agitation in people with
dementia. Haloperidol, olanzapine, quetiapine,
risperidone, aripiprazole, ziprasidone and lorazepam significantly reduced the level of agitation in
people with agitation related to acute psychosis.
The risk of sedation, and potentially associated
respiratory impairment, appears to be higher for
first-generation antipsychotics, benzodiazepines,
dexmedetomidine, and the antidepressants considered (i.e. mirtazapine and trazodone). All
antipsychotics have warnings or explicit contraindications for the use in people with risk of QTc
prolongation and for the association with some of
the commonly used anti-COVID medical treatments. From a regulatory standpoint, only few
medications have a marketing authorisation for at
least one of the conditions considered. In particular, only haloperidol has an explicit indication for
delirium according to the EMA, while midazolam
and promazine have a generic indication for psychomotor agitation (Table 1). For many of the
selected medications, rapidly acting formulations
are not available on the market, although this
aspect can notably vary according to the country
and context (e.g. humanitarian and low-resources
settings).
Discussion
Only quetiapine and dexmedetomidine showed
benefits over placebo for the treatment of delirium in ICU settings, while no medications had
3
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10–60 mg
(Continued)

1–4 mg
(elderly 0.5–2)

20–150 mg
(elderly 5–150 mg)

10–80 mg

100–400 mg

0.5–2 mg

25–50 mg

100–200 mg × 4
(elderly 25–50 mg)

3–6 mg

2.5–5 mg

1–10 mg
(elderly 0.5–5 mg)

25–300 mg
(elderly 25–75 mg)

10–30 mg

Suggested daily
doses

Table 1. Clinical elements, evidence of benefit and regulatory information of candidate medications for the treatment of hyperactive delirium in people with COVID-19.
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TAB, tablets or capsules.
Evidence of benefit was reported for treatments showing statistical superiority over placebo at study endpoint according to the most updated meta-analysis of RCTs. If data from
placebo-controlled trials were lacking, we considered head-to-head RCTs showing no significant differences against haloperidol and narrow confidence intervals according to the GRADE
approach for detecting imprecision, provided that haloperidol was effective versus placebo in the same population.
Notes on registered indications: (a) Registered indication (BNF): Psychomotor agitation, excitement, and violent or dangerously impulsive behaviour; (b) Registered indication (BNF):
Short-term adjunctive management of psychomotor agitation; Agitation and restlessness in elderly; (c) Registered indication (BNF): Short-term treatment (up to 6 weeks) of persistent
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Registered indication (BNF): Adjunct to antipsychotic for confusion and restlessness in palliative care; (e) Registered indication (BNF): Mild to moderate dementia in Alzheimer’s disease
and in Parkinson’s disease; (f) Registered indication (BNF): Mild to moderate dementia in Alzheimer’s disease.
Notes on EMA/BFN warnings and precautions: all antipsychotics have a warning for (a) the increased risk QTc prolongation (and for haloperidol and ziprasidone there is contraindication
if QTc ⩾500 ms) and (b) the increased risk of death in older people with dementia. Haloperidol is contraindicated in association with other QTc-prolonging medications, including certain
antibiotics and chloroquine. The risk of QTc prolongation is likely to be greater with intravenous route. The associations quetiapine + cytochrome P450 3A4 inhibitors (e.g. HIV-protease
inhibitors, clarithromycin) and lorazepam + HIV-protease inhibitors are contraindicated. Caution should be observed for any antipsychotic in association with other QTc-prolonging
medications, for midazolam in association with HIV-protease inhibitors and macrolide antibiotics, and for trazodone in association with ritonavir and macrolide antibiotics.
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evidence of benefit over placebo in non-ICU settings. A recent network meta-analysis pooling
data from studies in both ICU and non-ICU settings found that only haloperidol (alone or combined with lorazepam) was slightly more effective
versus inactive treatments in terms of response.37
However, in this analysis, placebo-controlled
studies and studies employing usual care as a control group were pooled together, notably limiting
the interpretation of the results.
Only the second-generation antipsychotics risperidone and aripiprazole showed benefits in two different populations, and only quetiapine in three.
Interestingly, like haloperidol, at least risperidone
and aripiprazole are not generally characterized by
a relevant sedative effect in the short-term, supporting the idea that sedation may not be the only
therapeutic target for the management of delirium.
High heterogeneity emerged between medications
regarding sedative proprieties, anticholinergic
effect, QTc prolongation and interactions with
anti-COVID treatments. These elements should
be carefully weighed on a case-by-case basis, in
light of underlying medical risk factors of patients
(Table 1). Particularly, in patients with COVID19, the risk of excessive sedation, respiratory distress, and QTc-prolonging drug–drug interactions
should be routinely considered. Furthermore,
most antipsychotics have an EMA warning on the
increased risk of death in people with dementia.38
This warning was issued on the basis of observational long-term studies showing a higher risk for
a number of conditions (including infections, cerebrovascular events, and overall risk of death)39;
however mortality was not increased in the
included short-term studies.30,31,34,37 Similarly,
acceptability (total dropouts),27,29 tolerability
(dropouts due to adverse events),29 and overall
adverse events were not increased,28,34 although
for risperidone and olanzapine a higher risk of cerebrovascular events in people with dementia was
found in short-term studies (⩽10 weeks).34
Regulatory data indicated that most of the medications considered are off-label in people with
COVID-19 and delirium, and their prescription
should therefore strictly follow the medico-legal
procedures for off-label prescribing, being particularly alert of any unexpected safety issues.40 This
situation applies particularly to people with
COVID-19, considering that many medical
treatments are similarly being used off-label or
compassionately.41
6

Pragmatically, some medications might have a
limited use in clinical practice, as they may not be
widely available as rapidly acting formulations,
such as for example as sublingual tablets, drops,
intramuscular injections, intravenous or subcutaneous infusions (Table 1).
This rapid review of the literature summarized previously provided an overview of the evidence base,
the clinical aspects, and the regulatory elements
that can help clinicians tailor the choice of antidelirium medications in different clinical scenarios.
Clinically relevant specific elements for people with
COVID-19 were critically considered. However,
some limitations should be acknowledged. First,
we employed a rapid review methodology, which
carries intrinsic limitations in terms of accuracy of
the search and selection process. Second, all available evidence suffers from a relevant degree of indirectness in terms of population, also considering
that studies on delirium often included patients
with hypoactive features (although relatively few in
most cases). Third, we employed a minimumthreshold criterion for identifying evidence of benefit, and details on the magnitude of treatment
effect were not provided in most cases.
In conclusion, while current guidelines recommend
treating delirium in people with COVID-19 following the same pharmacological approach as used in
the general population, COVID-19 provides a paradigmatic example of how standard treatment procedures, being designed around ‘average’ patients, are
hardly applicable as complexity increases. Hopefully,
the present tabular representation of the main clinical considerations relevant for the treatment of
delirium in people with COVID-19 can help inform
treatment choices that health care professionals
need to make under real-world clinical circumstances. Quetiapine, risperidone and aripiprazole
are potentially effective medications for the shortterm treatment of hyperactive delirium, and might
represent an alternative to conventional treatments,
such as haloperidol. Of note, although the focus of
this review was on pharmacological treatments,
non-pharmacological approaches remain a cornerstone of the treatment and prevention of delirium,
and should be provided whenever possible (e.g.
reorientation of the patient, reviewing medications,
managing visual and hearing impairment).
In terms of research priorities, we call for innovative approaches to establish the beneficial and
harmful consequences of different medications in
people with delirium, including in highly complex
journals.sagepub.com/home/tpp
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populations (such as COVID-19) where standard
treatments might be unfeasible. In particular,
pragmatic randomised head-to-head studies
enrolling real-world patients are urgently needed,
which test promising medications with safe profiles (e.g. aripiprazole, quetiapine, risperidone,
valproate, dexmedetomidine), and employ hard
outcome measures resembling those routinely
used in clinical practice.
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